Amneal Pharma (AMRX)
NASDAQ:AMRX
Want to see AMRX full AI Analyst Report?
AMRX Stock Chart & Stats
$13.91
$0.07(0.89%)
At close: 4:00 PM EST
$13.91
$0.07(0.89%)
Day’s Range― - ―
52-Week Range$7.07 - $15.42
Previous CloseN/A
Volume380.73K
Average Volume (3M)1.63M
Market Cap
$4.04B
Enterprise Value$6.70B
Total Cash (Recent Filing)$197.66M
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)34.0
Beta0.88
Next Earnings
Aug 12, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.38
Shares Outstanding319,022,800
10 Day Avg. Volume1,621,226
30 Day Avg. Volume1,632,190
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap1.66
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda10.70
Forecast
1Y Price Target
$17.25Price Target Upside24.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.98
Revenue Forecast (FY)$3.09B
Bulls Say, Bears Say
Bulls Say
Biosimilars & GLP-1 Strategic PushAmneal’s push into biosimilars and GLP‑1 manufacturing represents a structural move up‑market from commodity generics. Approvals and a multi‑year target for six U.S. biosimilars plus a Pfizer collaboration expand addressable markets, increase entry barriers, and create higher‑margin, longer‑duration revenue streams.
Improving Cash Generation And MarginsConsistent positive free cash flow (~$205M TTM) and materially improved gross and EBITDA margins underpin financial resilience. Durable FCF supports ongoing R&D, complex launches and deleveraging, reducing the time needed to shrink leverage versus a purely loss-making generics profile.
Kashiv Acquisition Expands Biosimilars PlatformThe Kashiv deal is a structural, strategic bolt‑on to integrate development, commercialization and scale in biosimilars. It accelerates Amneal’s biologics capabilities, broadens pipeline and commercial reach, and aims to capture loss‑of‑exclusivity opportunities that are less price‑sensitive than small‑molecule generics.
Bears Say
High Leverage And Negative EquityMaterial leverage and a negative equity position weaken financial flexibility and amplify refinancing and downturn risk. Even with improving cash flow, high absolute debt levels constrain capital allocation, raise interest‑coverage sensitivity, and limit ability to absorb execution delays without additional financing.
Execution Risk From Many Dependent InitiativesThe company’s recovery relies on multiple complex, timing‑sensitive projects. Delays or setbacks across biosimilars, GLP‑1 manufacturing, or complex ANDA launches would defer higher‑margin revenue and weaken near‑term cash flow, making medium‑term targets contingent on operational execution across many fronts.
AvKARE Revenue Reset And Channel ConcentrationA meaningful expected decline in AvKARE revenue reflects both deliberate strategy and lost product sales, exposing variability in government‑channel revenues. Given AvKARE’s size, such resets can reduce cash flow and make near‑term margin progress more dependent on successful specialty and launch execution.
Amneal Pharmaceuticals News
AMRX FAQ
What was Amneal Pharma’s price range in the past 12 months?
Amneal Pharma lowest stock price was $7.07 and its highest was $15.42 in the past 12 months.
What is Amneal Pharma’s market cap?
Amneal Pharma’s market cap is $4.04B.
When is Amneal Pharma’s upcoming earnings report date?
Amneal Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Amneal Pharma’s earnings last quarter?
Amneal Pharma released its earnings results on May 07, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.169 by $0.101.
Is Amneal Pharma overvalued?
According to Wall Street analysts Amneal Pharma’s price is currently Undervalued.
Does Amneal Pharma pay dividends?
Amneal Pharma does not currently pay dividends.
What is Amneal Pharma’s EPS estimate?
Amneal Pharma’s EPS estimate is 0.23.
How many shares outstanding does Amneal Pharma have?
Amneal Pharma has 319,022,800 shares outstanding.
What happened to Amneal Pharma’s price movement after its last earnings report?
Amneal Pharma reported an EPS of $0.27 in its last earnings report, beating expectations of $0.169. Following the earnings report the stock price went down -3.79%.
Which hedge fund is a major shareholder of Amneal Pharma?
Currently, no hedge funds are holding shares in AMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amneal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (24.01% Upside)
$17.25 (24.01% Upside)
Blogger Sentiment
Bullish
AMRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 90.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $450.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.2%
Last 30 Days ▲ 28.3%
Last 30 Days ▲ 28.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.48%
12-Months-Change
Fundamentals
Return on Equity
-144.72%
Trailing 12-Months
Asset Growth
5.20%
Trailing 12-Months
Company Description
Amneal Pharma
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
AMRX Company Deck
AMRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a decisive strategic move — the Kashiv acquisition — that meaningfully expands Amneal's addressable market, vertical capabilities, and long‑term growth runway in biosimilars. Q1 results showed strong top‑ and bottom‑line execution (revenues +4%, adjusted EBITDA +19%, adjusted EPS +29%), margin expansion, specialty product momentum, and improving leverage. Near‑term challenges include transaction‑related cash/financing impacts, modest near‑term dilution and guidance cadence (some 2027 EBITDA conservatism), integration and execution risk inherent to complex biologics development, and required CapEx to scale capacity. On balance, the positives around scale, pipeline, synergies ($400M–$500M), and improved long‑term financial trajectory outweigh the short‑term costs and execution risks.View all AMRX earnings summariesAMRX Stock 12 Month Forecast
Average Price Target
$17.25
▲(24.01% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Alvotech
―
Ownership Overview
17.08% Insiders
11.66% Mutual Funds
13.96% Other Institutional Investors
41.90% Public Companies and Individual Investors